Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. on a voluntary basis. FZ-AD004 antibody drug conjugate for injection (Trop2-BB05 ADC, the "Drug") for the treatment of advanced solid tumors of the Company is undergoing phase I clinical study (the "Study"), and the first patient has recently been successfully enrolled in the Study.

The Company has received the acceptance notice for the investigational new drug application in January 2023. The Study of the Drug aims to evaluate its safety, tolerability and pharmacokinetics as well as to preliminarily evaluate the therapeutic efficacy in patients with advanced solid tumors. As at the date on the publication of this announcement, the first patient has been successfully enrolled in the Study.